Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology
Phio Pharmaceuticals (NASDAQ: PHIO) announced the publication of research on RXI-231, an INTASYL compound designed to treat hyperpigmentation, in Clinical, Cosmetic and Investigational Dermatology's December 2024 issue. The study demonstrates that RXI-231 effectively reduces tyrosinase (TYR) gene expression and melanin content in human melanocytes and 3D epidermal cultures.
The research shows that applying RXI-231 every other day visibly reduced pigmentation in 3D epidermal cultures. Testing using the MatTek EpiDerm Skin Irritation model confirmed the compound's non-irritant profile. While additional clinical testing is required, RXI-231 shows promise for treating hyperpigmentation disorders.
Phio Pharmaceuticals (NASDAQ: PHIO) ha annunciato la pubblicazione di una ricerca su RXI-231, un composto INTASYL progettato per trattare l'iperpigmentazione, nel numero di dicembre 2024 di Clinical, Cosmetic and Investigational Dermatology. Lo studio dimostra che RXI-231 riduce efficacemente l'espressione del gene della tirosinasi (TYR) e il contenuto di melanina nei melanociti umani e nelle culture epidermiche 3D.
La ricerca mostra che l'applicazione di RXI-231 ogni due giorni ha ridotto visibilmente la pigmentazione nelle culture epidermiche 3D. I test condotti con il modello di irritazione cutanea MatTek EpiDerm hanno confermato il profilo non irritante del composto. Anche se sono necessari ulteriori test clinici, RXI-231 mostra promettente potenzialità nel trattamento dei disturbi dell'iperpigmentazione.
Phio Pharmaceuticals (NASDAQ: PHIO) anunció la publicación de una investigación sobre RXI-231, un compuesto INTASYL diseñado para tratar la hiperpigmentación, en el número de diciembre de 2024 de Clinical, Cosmetic and Investigational Dermatology. El estudio demuestra que RXI-231 reduce eficazmente la expresión del gen de la tirosinasa (TYR) y el contenido de melanina en melanocitos humanos y cultivos epidérmicos 3D.
La investigación muestra que aplicar RXI-231 cada dos días redujo visiblemente la pigmentación en los cultivos epidérmicos 3D. Las pruebas realizadas utilizando el modelo de irritación cutánea MatTek EpiDerm confirmaron el perfil no irritante del compuesto. Si bien se requieren pruebas clínicas adicionales, RXI-231 muestra promesas para el tratamiento de los trastornos de hiperpigmentación.
Phio Pharmaceuticals (NASDAQ: PHIO)는 임상, 미용 및 실험 피부학 저널 2024년 12월호에 하이퍼피그멘테이션 치료를 위해 설계된 INTASYL 화합물인 RXI-231에 대한 연구 결과를 발표했다고 전했습니다. 연구에 따르면 RXI-231은 인간 멜라노사이트 및 3D 표피 배양에서 티로시나제(TYR) 유전자 발현과 멜라닌 함량을 효과적으로 감소시킵니다.
연구 결과 RXI-231을 이틀에 한 번 적용하면 3D 표피 배양에서 색소 침착이 눈에 띄게 감소했습니다. MatTek EpiDerm 피부 자극 모델을 사용한 테스트에서 이 화합물의 비자극성 프로필이 확인되었습니다. 추가 임상 테스트가 필요하지만 RXI-231은 하이퍼피그멘테이션 장애 치료에 대한 가능성을 보입니다.
Phio Pharmaceuticals (NASDAQ: PHIO) a annoncé la publication d'une recherche sur RXI-231, un composé INTASYL conçu pour traiter l'hyperpigmentation, dans le numéro de décembre 2024 de Clinical, Cosmetic and Investigational Dermatology. L'étude démontre que RXI-231 réduit efficacement l'expression du gène de la tyrosinase (TYR) et le contenu en mélanine dans des mélanocytes humains et des cultures épidermiques 3D.
La recherche montre que l'application de RXI-231 tous les deux jours réduit visiblement la pigmentation dans les cultures épidermiques 3D. Les tests utilisant le modèle d'irritation cutanée MatTek EpiDerm ont confirmé le profil non irritant du composé. Bien que des tests cliniques supplémentaires soient nécessaires, RXI-231 montre des promesses pour le traitement des troubles de l'hyperpigmentation.
Phio Pharmaceuticals (NASDAQ: PHIO) gab die Veröffentlichung einer Forschung zu RXI-231, einer INTASYL-Verbindung zur Behandlung von Hyperpigmentierung, in der Dezemberausgabe 2024 von Clinical, Cosmetic and Investigational Dermatology bekannt. Die Studie zeigt, dass RXI-231 die Expression des Tyrosinase-Gens (TYR) und den Melaningehalt in menschlichen Melanozyten und 3D-epidermalen Kulturen effektiv verringert.
Die Forschung zeigt, dass die Anwendung von RXI-231 jeden zweiten Tag die Pigmentierung in 3D-epidermalen Kulturen sichtbar reduzierte. Tests mit dem MatTek EpiDerm-Hautirritationsmodell bestätigten das nicht reizende Profil des Wirkstoffs. Während weitere klinische Tests erforderlich sind, zeigt RXI-231 vielversprechende Ansätze zur Behandlung von Hyperpigmentierungsstörungen.
- Successful proof-of-concept data showing RXI-231's effectiveness in reducing pigmentation
- Confirmation of RXI-231's non-irritant profile through MatTek EpiDerm testing
- Publication in a peer-reviewed international journal validating research quality
- Additional clinical testing required before commercialization
- No immediate revenue potential from this early-stage research
Insights
The publication of RXI-231's preclinical data in a peer-reviewed journal marks a scientific validation milestone, but carries immediate market impact. The compound shows promising mechanism-specific activity against tyrosinase and melanin production in controlled laboratory settings. However, the research remains at an early proof-of-concept stage without human clinical data or clear commercialization timeline.
The dermatology market for hyperpigmentation treatments represents a
For a micro-cap company with
INTASYL Compound RXI-231: a promising approach to treatment of hyperpigmentation
Marlborough, Massachusetts--(Newsfile Corp. - January 2, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the publication of research entitled, Self-delivering RNAi Compounds for Reduction of Hyperpigmentation, in the December, 2024 issue of Clinical, Cosmetic and Investigational Dermatology.
The article presents proof-of-concept data for RXI-231, an INTASYL compound designed to target and reduce tyrosinase (TYR) gene expression. RXI-231 significantly reduced tyrosinase mRNA expression, and correspondingly reduced in melanin content in both normal human melanocytes and the 3D human epidermal culture, Melano Derm model. Application of INTASYL RXI-231 every other day visibly reduced pigmentation in the 3D epidermal cultures. RXI-231 was also evaluated using the MatTek EpiDerm Skin Irritation model which confirmed its non-irritant profile. While further characterization and clinical testing is needed, RXI-231 shows promise in treating hyperpigmentation disorders.
Clinical, Cosmetic and International Dermatology is an international, peer-reviewed journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. Key topics for the journal include normal and pathological process in skin aging, their modification and treatment, as well as basic research into the histology of dermal and dermal structures that provide clinical insights and potential treatment options
"We are delighted to see this publication which presents a summary of INTASYL compound RXI-231's uniqueness in addressing its selective targeting of TYR gene expression, and underscores the innovative and expansive potential of INTASYL compounds in dermatological conditions," said Robert Bitterman, CEO, Phio Pharmaceuticals.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company advancing its proprietary INTASYL siRNA gene silencing technology to eliminate cancer. INTASYL can target and silence virtually any gene with high degree of specificity across a wide range of cell types and tissues. INTASYL is designed to enhance the ability of immune cells to more effectively kill tumor cells. INTASYL has also demonstrated enhancement adoptive cell therapy. Notably, INTASYL is a self-delivering RNAi technology focused on immuno-oncology therapeutics without the need for formulation enhancements or manipulations to reach its target.
Phio's lead clinical program, PH-762, is an INTASYL compound that silences PD-1. PH-762 is a potential non-surgical treatment for skin cancers. The on-going Phase 1b trial (NCT# 06014086) received FDA clearance for an Investigational New Drug Application to evaluate PH-762 in the treatment of cutaneous SCC, melanoma and Merkel cell carcinoma in second quarter of 2023.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells and statements regarding our commercial and clinical strategy, development plans and timelines and other future events.
These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235729
FAQ
What are the key findings of PHIO's RXI-231 research published in December 2024?
How does Phio Pharmaceuticals' RXI-231 compound treat hyperpigmentation?
What safety testing has been completed for PHIO's RXI-231 compound?
When will PHIO's RXI-231 be available for clinical use?
